Engineering Chimeric Antigen Receptor T-Cells against Immune Checkpoint Inhibitor Pd1 and Pd-L1 for Treating Pancreatic Cancer

Medicine & Life Sciences

1. Chimeric Antigen Receptors 100%
2. T-Lymphocytes 34%
3. Pancreatic Neoplasms 29%
4. Neoplasms 17%
5. atezolizumab 9%
6. Survival Rate 9%
7. Cytokines 7%
8. Immune Tolerance 7%
9. Tumor Microenvironment 6%
10. Heterografts 5%
11. Immunotherapy 5%
12. In Vitro Techniques 5%
13. Anti-Idiotypic Antibodies 5%
14. Therapeutic Uses 5%